Abstract | BACKGROUND:
Urokinase plasminogen activator receptor (uPAR) expression has been shown to correlate with poor prognosis in colorectal cancer (CRC). The authors hypothesized that targeting uPAR, a receptor involved in cell proliferation, migration, invasion, adhesion, and angiogenesis, would impair the growth of CRC in the liver, the most common site of metastasis. METHODS: Human CRC cell lines were examined for uPAR expression by Western blot analysis. The in vitro effects of the uPAR monoclonal antibody (MoAb) (ATN-658) were tested in proliferation and migration assays. For in vivo studies, human HCT116 CRC cells were injected directly into the livers of mice in 2 separate studies, the first to determine the effect of therapy with ATN-658 on small-volume disease ( therapy begun on Day 4), and a second study to determine the effect of therapy on established disease ( therapy begun on Day 12). Mice were randomized to receive either nonspecific immunoglobulin G MoAb (control) or ATN-658, and were sacrificed 1 month after tumor implantation. RESULTS: uPAR was expressed by all CRC cell lines studied. In vitro, ATN-658 had minimal effect on CRC proliferation in monolayers, but significantly decreased CRC cell migration. In vivo, ATN-658 lead to significant reductions in tumor growth versus control when initiated either 4 or 12 days after tumor implantation (-65% vs control [P < or = .05] and -85% vs control [P < or = .05]). ATN-658 significantly inhibited in vivo tumor cell proliferation in both studies. CONCLUSIONS: uPAR MoAb therapy impaired CRC tumor growth in the liver in both small-volume and large-volume disease models.
|
Authors | George Van Buren 2nd, Michael J Gray, Nikolaos A Dallas, Ling Xia, Sherry J Lim, Fan Fan, Andrew P Mazar, Lee M Ellis |
Journal | Cancer
(Cancer)
Vol. 115
Issue 14
Pg. 3360-8
(Jul 15 2009)
ISSN: 0008-543X [Print] United States |
PMID | 19484792
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- ATN-658
- Antibodies, Monoclonal
- Receptors, Urokinase Plasminogen Activator
|
Topics |
- Animals
- Antibodies, Monoclonal
(pharmacology)
- Cell Line, Tumor
- Cell Movement
(drug effects)
- Cell Proliferation
(drug effects)
- Colorectal Neoplasms
(pathology)
- Humans
- Liver Neoplasms, Experimental
(prevention & control, secondary)
- Male
- Mice
- Mice, Nude
- Neoplasm Transplantation
- Random Allocation
- Receptors, Urokinase Plasminogen Activator
(immunology)
- Xenograft Model Antitumor Assays
|